Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesControl Bionics Ltd

Control Bionics Ltd

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.054 AUD 0.00 ( 8.00%)
Last update at 2026-11-12T04:57:00Z
VOLUME
1010254
Market Cap
26.66M

Momentum Score

…

Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, Japan, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. The company also provides the NeuroStrip, a wearable, miniaturized electromyography device; NeuroNode, a wireless, wearable sensor that allows users to access technology through bioelectric signals and spatial movements; and Cosmos Connect, a small portable control device that turns a single NeuroNode sensor into multiple outputs. In addition, it offers mounting systems under the Rehadapt brand, including wheelchair mounts, floor stands, and table stands; and switch systems comprising proximity, press, and finger switches. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is headquartered in Cremorne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.05
Low
0.06
High
52 Week Price Range
0.04
Low
0.10
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Control Bionics Ltd develops and commercializes non-invasive assistive communication and control technologies for people with severe neurological and motor impairments. Long-term growth may be supported by aging populations, rising recognition of neurodegenerative conditions, increased adoption of assistive devices and international distribution expansion. The company appears positioned to offer exposure to a niche medical-technology market with potential recurring revenue from device and service sales.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.05
Dividend Yield
-
Revenue TTM
4.77M
Revenue Per Share
0.01
Gross Profit TTM
2.36M
Debt / Equity
0.10
ROE
-122.92%
Net Debt
-1.46M
ROCE
-115.14%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -7.72M -6.11M -5.91M -5.63M -6.10M
Net income -7.27M -6.11M -5.91M -5.63M -6.11M
Selling general administrative - 1.54M 5.67M 5.29M 4.91M
Selling and marketing expenses - 0.41M 0.46M 0.62M 0.71M
Gross profit -4.14M 4.11M 3.90M 3.71M -2.91M
Reconciled depreciation - - 0.84M 0.48M 0.51M
Ebit - -5.96M -5.86M -5.62M -6.43M
Ebitda -7.29M -5.14M -5.01M -5.14M -5.92M
Depreciation and amortization - 0.82M 0.84M 0.48M 0.51M
Operating income -7.29M -5.83M -5.93M -5.21M -6.01M
Other operating expenses 12.06M 11.97M 12.22M 11.72M 10.99M
Interest expense 0.08M 0.11M 0.06M 0.02M 0.01M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.18M 0.01M 0.02M 0.00M
Net interest income - - -0.04M -0.00M -0.04M
Income tax expense -0.45M -0.43M -0.85M -0.41M -0.34M
Total revenue 4.77M 6.14M 5.35M 5.64M 4.50M
Total operating expenses 3.15M 9.94M 4.47M 4.22M 9.01M
Cost of revenue 8.91M 2.03M 1.45M 1.93M 7.42M
Total other income expense net -0.43M -0.28M 0.02M -0.42M -0.09M
Net income from continuing ops - - -5.91M -5.63M -6.10M
Net income applicable to common shares - -6.11M -5.91M -5.63M -6.10M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 9.05M 8.23M 9.03M 8.70M 13.44M
Intangible assets 3.76M 3.88M - 4.11M 4.07M
Other current assets 0.30M 0.69M 0.19M 0.20M 0.71M
Total liab 2.73M 2.72M 2.76M 1.55M 1.51M
Total stockholder equity 6.31M 5.51M 6.27M 7.15M 11.92M
Other current liab 1.19M 0.86M 0.85M 0.89M 0.77M
Common stock 46.14M 40.37M 35.15M 30.24M 29.27M
Capital stock - - - 30.24M 29.27M
Retained earnings -42.65M -35.39M -29.28M -23.37M -17.73M
Other liab - - - 0.02M 0.03M
Good will 0.75M - - - -
Other assets - - - 0.00M 0.02M
Cash 2.08M 0.59M 0.98M 0.94M 5.21M
Total current liabilities 2.72M 2.55M 2.40M 1.53M 1.36M
Current deferred revenue - - 0.32M - -
Net debt -1.46M -0.16M -0.02M -0.81M -4.93M
Short term debt 0.62M 0.30M 0.63M 0.13M 0.16M
Short long term debt - - - - 0.05M
Short long term debt total 0.62M 0.44M 0.96M 0.13M 0.28M
Other stockholder equity 48.97M - - 0.09M 0.39M
Property plant equipment - - - 0.72M 0.71M
Total current assets 4.18M 3.17M 3.76M 3.87M 8.61M
Net tangible assets - - - 3.04M 7.83M
Short term investments - 0.08M - - -
Net receivables 1.35M 1.40M 2.19M 1.78M 1.76M
Inventory 0.45M 0.41M 0.40M 0.80M 0.92M
Accounts payable 0.90M 1.39M 0.61M 0.52M 0.43M
Accumulated other comprehensive income 2.82M 0.53M 0.39M 0.27M 0.39M
Non currrent assets other - - 4.05M - 0.02M
Non current assets total 4.86M 5.06M 5.27M 4.83M 4.83M
Capital lease obligations - - - 0.13M 0.24M
Long term debt total - - - 0.00M 0.12M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - -0.47M -0.46M -0.15M
Change to liabilities - - - 0.32M -0.01M
Total cashflows from investing activities -0.27M -0.74M -0.47M -0.46M -0.15M
Net borrowings - - 0.52M -0.16M -0.05M
Total cash from financing activities 7.49M 4.63M 5.43M 0.71M -0.09M
Change to operating activities - - - -0.31M 0.06M
Net income -7.27M -6.11M -5.91M -5.63M -6.11M
Change in cash 1.48M -0.39M 0.05M -4.28M -7.12M
Begin period cash flow 0.59M 0.98M 0.94M 5.21M 12.33M
End period cash flow 2.08M 0.59M 0.98M 0.94M 5.21M
Total cash from operating activities -5.75M -4.27M -4.91M -4.53M -6.89M
Issuance of capital stock - - 5.09M 0.75M 0.01M
Depreciation - 0.99M 0.84M 0.48M 0.51M
Other cashflows from investing activities -0.06M -0.44M -0.07M -0.04M -
Change to inventory -0.04M -0.01M -0.05M 0.12M -0.65M
Change to account receivables 0.23M -0.07M -0.76M -0.24M -0.42M
Sale purchase of stock - 5.41M -0.11M 0.86M 0.01M
Other cashflows from financing activities -0.24M -0.42M -0.07M -0.05M -0.01M
Change to netincome - - - 0.74M -0.27M
Capital expenditures 0.01M 0.30M 0.47M 0.46M 0.15M
Change in working capital -0.04M -0.03M -0.46M -0.11M -1.02M
Stock based compensation - 0.12M 0.14M 0.04M 0.05M
Other non cash items 1.56M 0.76M 0.62M 1.50M 4.32M
Free cash flow -5.76M -4.57M -5.38M -4.98M -5.75M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CBL
Control Bionics Ltd		 0.00
8.00%		 0.05 - - 5.59 4.22 5.19 -2.23
COH
Cochlear Ltd		 2.26
1.50%		 152.98 68.64 27.40 4.30 5.34 3.97 28.09
IMR
Imricor Medical Systems Inc		 0.06
4.72%		 1.33 - - 36401.21 17.45 4019.33 -2.60
AVR
Anteris Technologies Global Corp		 0.50
5.88%		 9.00 - - 356.02 2.19 130.34 -5.20
AVH
Avita Medical Inc		 -0.11
2.13%		 5.06 - 9.97 9.59 7.17 6.76 15.37

Profile*

Control Bionics Ltd

Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, Japan, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. The company also provides the NeuroStrip, a wearable, miniaturized electromyography device; NeuroNode, a wireless, wearable sensor that allows users to access technology through bioelectric signals and spatial movements; and Cosmos Connect, a small portable control device that turns a single NeuroNode sensor into multiple outputs. In addition, it offers mounting systems under the Rehadapt brand, including wheelchair mounts, floor stands, and table stands; and switch systems comprising proximity, press, and finger switches. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is headquartered in Cremorne, Australia.

11-13 Pearson Street, Cremorne, VIC, Australia, 3121

61 3 9897 3576

https://www.controlbionics.com

Name Title Year Born
Mr. Peter Shann Ford Founder, Interim CEO, Exec. Director & Director of Innovation NA
Mr. Robert William Wong Exec. Director NA
Mr. Todd Tyler US Country Mang. NA
Dominik Kucera Interim Chief Financial Officer NA
Mr. James Schorey Chief Technology Officer NA
Ms. Meagan Koeneman Sales Director NA
Mr. Brett Thomas Crowley B.Com., BCom, C.A., CA, DipLaw Company Sec. 1957
Mr. Jeremy E. Steele CEO, MD & Director NA
Mr. Peter Shann Ford Founder & Non-Executive Director NA
Mr. Dominik Kucera Interim Chief Financial Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…